Safety of infliximab in inflammatory bowel disease needs to be debated

Clin Gastroenterol Hepatol. 2009 May;7(5):603-4. doi: 10.1016/j.cgh.2008.12.021. Epub 2008 Dec 27.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Child
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab
  • Middle Aged
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Immunologic Factors
  • Infliximab